Dashboard
1
Poor Management Efficiency with a low ROE of 1.71%
- The company has been able to generate a Return on Equity (avg) of 1.71% signifying low profitability per unit of shareholders funds
2
Poor long term growth as Operating profit has grown by an annual rate 0.56% of over the last 5 years
3
The company declared positive results in Dec'24 after negative results in Jun'24
4
With ROE of 11.47%, it has a very attractive valuation with a 1.22 Price to Book Value
5
Consistent Underperformance against the benchmark over the last 3 years
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
4.98%
0%
4.98%
6 Months
-13.21%
0%
-13.21%
1 Year
-26.65%
0%
-26.65%
2 Years
-19.61%
0%
-19.61%
3 Years
-58.44%
0%
-58.44%
4 Years
-56.28%
0%
-56.28%
5 Years
-59.93%
0%
-59.93%
PureTech Health Plc for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-12.70%
EBIT Growth (5y)
0.56%
EBIT to Interest (avg)
-17.27
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.87
Sales to Capital Employed (avg)
0.02
Tax Ratio
Tax Ratio is Negative%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0.02%
ROCE (avg)
0
ROE (avg)
1.71%
Valuation key factors
Factor
Value
P/E Ratio
11
Industry P/E
Price to Book Value
1.22
EV to EBIT
-1.16
EV to EBITDA
-1.19
EV to Capital Employed
2.30
EV to Sales
21.27
PEG Ratio
0.08
Dividend Yield
NA
ROCE (Latest)
-199.17%
ROE (Latest)
11.47%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
Shareholding Snapshot : Dec 2024
Shareholding Compare (%holding) 
Majority shareholders
Strategic Entities
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 0 Foreign Institutions (0%)
Strategic Entities with highest holding
Highest Public shareholder
Annual Results Snapshot (Consolidated) - Dec'23
Dec'23
Dec'22
Change(%)
Net Sales
2.70
12.70
-78.74%
Operating Profit (PBDIT) excl Other Income
-113.60
-153.40
25.95%
Interest
10.90
3.20
240.62%
Exceptional Items
64.80
78.40
-17.35%
Consolidate Net Profit
-53.60
-30.10
-78.07%
Operating Profit Margin (Excl OI)
-43,903.90%
-12,665.30%
-3,123.86%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2023 is -78.74% vs 0.79% in Dec 2022
Consolidated Net Profit
YoY Growth in year ended Dec 2023 is -78.07% vs 33.99% in Dec 2022
About PureTech Health Plc 
PureTech Health Plc
Pharmaceuticals & Biotechnology
PureTech Health PLC is a clinical stage biotechnology company. The Company is engaged in discovering, developing and commercializing medicines for diseases, including intractable cancers, lymphatic and gastrointestinal diseases, central nervous system disorders, and inflammatory and immunological diseases, among others. Its segments include Internal and Affiliates. The Internal division is focused on advancing a pipeline fueled by discoveries in lymphatics and immune cell trafficking to modulate disease in a tissue-specific manner. The Affiliates segment is comprised of the programs within its Affiliates division that are consolidated operational subsidiaries that have research and development programs. Its wholly owned pipeline includes various candidates, such as LYT-100, LYT-200, LYT-210, Lymphatic Targeting Chemistry Platform, Milk Exosome Platform and Meningeal Lymphatics Platform.
Company Coordinates 
Company Details
501 Boylston St Ste 6102 , BOSTON MA : 02116-3769
Registrar Details






